Stan­ford spin­out Forty Sev­en ar­rives at AS­CO with a snap­shot of promis­ing CD47 da­ta — and a $115M IPO in hand

CHICA­GO — Here’s a neat trick for up-and-com­ing on­col­o­gy biotechs to con­sid­er.

Ex­ecs for Forty Sev­en, the CD47 star found­ed by Stan­ford’s leg­endary Irv Weiss­man …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER